SI3334744T1 - Pentaaza makrociklični obročni kompleksi, ki imajo peroralno biološko uporabnost - Google Patents

Pentaaza makrociklični obročni kompleksi, ki imajo peroralno biološko uporabnost

Info

Publication number
SI3334744T1
SI3334744T1 SI201630852T SI201630852T SI3334744T1 SI 3334744 T1 SI3334744 T1 SI 3334744T1 SI 201630852 T SI201630852 T SI 201630852T SI 201630852 T SI201630852 T SI 201630852T SI 3334744 T1 SI3334744 T1 SI 3334744T1
Authority
SI
Slovenia
Prior art keywords
oral bioavailability
macrocyclic ring
pentaaza macrocyclic
ring complexes
complexes possessing
Prior art date
Application number
SI201630852T
Other languages
English (en)
Inventor
Jeffery L. Keene
Otto F. SCHALL
Dennis P. Riley
Original Assignee
Galera Labs, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galera Labs, Llc filed Critical Galera Labs, Llc
Publication of SI3334744T1 publication Critical patent/SI3334744T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08—Copper compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/04—Nickel compounds
    • C07F15/045—Nickel compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201630852T 2015-08-11 2016-08-11 Pentaaza makrociklični obročni kompleksi, ki imajo peroralno biološko uporabnost SI3334744T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562203761P 2015-08-11 2015-08-11
EP16835928.9A EP3334744B1 (en) 2015-08-11 2016-08-11 Pentaaza macrocyclic ring complexes possessing oral bioavailability
PCT/US2016/046599 WO2017027728A1 (en) 2015-08-11 2016-08-11 Pentaaza macrocyclic ring complexes possessing oral bioavailability

Publications (1)

Publication Number Publication Date
SI3334744T1 true SI3334744T1 (sl) 2020-10-30

Family

ID=57984526

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201630852T SI3334744T1 (sl) 2015-08-11 2016-08-11 Pentaaza makrociklični obročni kompleksi, ki imajo peroralno biološko uporabnost

Country Status (29)

Country Link
US (5) US10597415B2 (sl)
EP (2) EP3738967A1 (sl)
JP (3) JP7041959B2 (sl)
KR (1) KR20180064380A (sl)
CN (3) CN113416170A (sl)
AU (3) AU2016306568B2 (sl)
CA (1) CA2994845A1 (sl)
CL (1) CL2018000371A1 (sl)
CO (1) CO2018002544A2 (sl)
CY (1) CY1123960T1 (sl)
DK (1) DK3334744T3 (sl)
EA (1) EA201890471A1 (sl)
ES (1) ES2807528T3 (sl)
HK (1) HK1257313A1 (sl)
HR (1) HRP20201092T1 (sl)
HU (1) HUE049926T2 (sl)
IL (3) IL297735B1 (sl)
LT (1) LT3334744T (sl)
MX (2) MX2018001605A (sl)
MY (1) MY196401A (sl)
PH (1) PH12018500296A1 (sl)
PL (1) PL3334744T3 (sl)
PT (1) PT3334744T (sl)
RS (1) RS60558B1 (sl)
SG (1) SG10202002859QA (sl)
SI (1) SI3334744T1 (sl)
UA (1) UA126788C2 (sl)
WO (1) WO2017027728A1 (sl)
ZA (2) ZA201801546B (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2056675T (lt) 2006-10-12 2019-05-27 Galera Labs, Llc Burnos gleivinės mukozito gydymo būdai
CN103906756B (zh) 2011-09-26 2020-03-03 加莱拉实验室有限责任公司 用于治疗疾病的方法
PL3334744T3 (pl) 2015-08-11 2020-09-21 Galera Labs, Llc Kompleksy pierścienia makrocyklicznego pentaaza posiadające biodostępność po podaniu doustnym
US11219614B2 (en) 2016-09-01 2022-01-11 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
JP2020507598A (ja) 2017-02-15 2020-03-12 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ 局所腸送達のためのペンタアザマクロ環錯体
AU2018252003A1 (en) * 2017-04-13 2019-11-21 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
CN114502179A (zh) * 2019-10-10 2022-05-13 加莱拉实验室有限责任公司 含锰配合物的水性制剂的制备方法、制剂和治疗方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
WO1993002090A1 (en) * 1991-07-19 1993-02-04 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
NZ283279A (en) 1994-04-22 1998-01-26 Monsanto Co Magnetic resonance imaging compounds comprising paramagnetic metals, compositions and use thereof
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
EP0846003A1 (en) 1995-08-17 1998-06-10 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
EP0844889A1 (en) 1995-08-17 1998-06-03 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US20050171198A1 (en) 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
US20060270639A1 (en) 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
DE69813898T2 (de) 1997-11-03 2004-03-11 Duke University Substituierte porphyrinen
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
AU5048400A (en) 1999-05-27 2000-12-18 Monsanto Company Biomaterials modified with superoxide dismutase mimics
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
CA2399293C (en) 2000-02-08 2012-01-03 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
ATE464061T1 (de) 2001-01-05 2010-04-15 Metaphore Pharmaceuticals Inc Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
ATE439134T1 (de) 2001-01-19 2009-08-15 Nat Jewish Med & Res Center Medikament zum schutz in der radiotherapie
WO2002058686A2 (en) 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
WO2002071054A1 (en) 2001-03-02 2002-09-12 Metaphore Pharmaceuticals, Inc. Chromatography of metal complexes
WO2002100395A1 (en) 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
US20040132706A1 (en) 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
DE60238560D1 (de) 2001-11-01 2011-01-20 Uab Research Foundation Kombinationen aus anti-dr5-antikörpern und anti-dr4-antikörpern und weiteren therapeutischen agentien
AU2003229923A1 (en) 2002-04-16 2003-11-03 Isis Innovation Limited Curcumin for the prevention and/or treatment of tissue damage
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
GB0412893D0 (en) * 2004-06-10 2004-07-14 Univ Hull Novel antiviral macrocycle derivatives and metal complexes, incorporating bridged macrocycles
US8217166B2 (en) 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
WO2006078713A2 (en) 2005-01-19 2006-07-27 Metaphore Pharmaceuticals, Inc. Methotrexate combinations for treating inflammatory diseases
KR20070116066A (ko) 2005-03-31 2007-12-06 쉐링 코포레이션 스피로사이클릭 트롬빈 수용체 길항제
WO2007139897A1 (en) 2006-05-23 2007-12-06 University Of Utah Research Foundation Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
WO2008027547A2 (en) 2006-08-31 2008-03-06 The Brigham And Women's Hospital, Inc. Antioxidant therapies
LT2056675T (lt) * 2006-10-12 2019-05-27 Galera Labs, Llc Burnos gleivinės mukozito gydymo būdai
US8486928B2 (en) * 2007-11-14 2013-07-16 Galera Therapeutics Super-oxide dismutase mimetics
EP2259776A4 (en) 2008-02-29 2011-03-16 Eagle Pharmaceuticals Inc USEFUL TOPOTECAN SOLUTIONS
CN102026990A (zh) 2008-04-15 2011-04-20 因特蒙公司 丙型肝炎病毒复制的新颖抑制剂
EP2296645B1 (en) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
CN102822198B (zh) 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
CN103906756B (zh) 2011-09-26 2020-03-03 加莱拉实验室有限责任公司 用于治疗疾病的方法
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
PL3334744T3 (pl) 2015-08-11 2020-09-21 Galera Labs, Llc Kompleksy pierścienia makrocyklicznego pentaaza posiadające biodostępność po podaniu doustnym
AU2017260425B2 (en) 2016-05-03 2023-04-06 Galera Labs, Llc Combination therapy for cancer treatment

Also Published As

Publication number Publication date
HUE049926T2 (hu) 2020-11-30
JP2018525388A (ja) 2018-09-06
JP2024012401A (ja) 2024-01-30
DK3334744T3 (da) 2020-07-27
SG10202002859QA (en) 2020-05-28
CN113416170A (zh) 2021-09-21
AU2016306568B2 (en) 2021-01-07
US20170044193A1 (en) 2017-02-16
CO2018002544A2 (es) 2018-07-10
IL297735B1 (en) 2024-04-01
PH12018500296A1 (en) 2018-08-13
EP3334744A4 (en) 2019-03-06
IL297735A (en) 2022-12-01
CA2994845A1 (en) 2017-02-16
CL2018000371A1 (es) 2018-08-03
EA201890471A1 (ru) 2018-10-31
WO2017027728A9 (en) 2017-04-06
CY1123960T1 (el) 2022-03-24
PT3334744T (pt) 2020-07-28
HK1257313A1 (zh) 2019-10-18
ZA202001373B (en) 2021-10-27
US20210347796A1 (en) 2021-11-11
IL287546A (en) 2021-12-01
AU2016306568A1 (en) 2018-03-22
CN108350009B (zh) 2021-07-09
US9738669B2 (en) 2017-08-22
EP3738967A1 (en) 2020-11-18
MX2018001605A (es) 2018-09-26
JP2022023183A (ja) 2022-02-07
PL3334744T3 (pl) 2020-09-21
IL257346A (en) 2018-03-29
MY196401A (en) 2023-03-29
US20180237462A1 (en) 2018-08-23
KR20180064380A (ko) 2018-06-14
US10597415B2 (en) 2020-03-24
LT3334744T (lt) 2020-07-27
ZA201801546B (en) 2020-07-29
IL257346B (en) 2021-12-01
EP3334744A1 (en) 2018-06-20
AU2020289730A1 (en) 2021-01-21
ES2807528T3 (es) 2021-02-23
CN108350009A (zh) 2018-07-31
UA126788C2 (uk) 2023-02-08
US9738670B2 (en) 2017-08-22
JP7041959B2 (ja) 2022-03-25
WO2017027728A1 (en) 2017-02-16
AU2020289730B2 (en) 2022-11-10
HRP20201092T1 (hr) 2020-10-30
IL287546B2 (en) 2023-04-01
US20170042907A1 (en) 2017-02-16
IL287546B (en) 2022-12-01
RS60558B1 (sr) 2020-08-31
US20200223879A1 (en) 2020-07-16
AU2023200738A1 (en) 2023-03-09
MX2022010230A (es) 2022-09-19
US11066433B2 (en) 2021-07-20
EP3334744B1 (en) 2020-04-22
CN113402560A (zh) 2021-09-17

Similar Documents

Publication Publication Date Title
IL287546B (en) Macrocyclic ring pentase complexes with oral bioavailability
AU365267S (en) Ring
TWD174459S (zh) 戒指
GB2532789B (en) Absolute rotary encoder
ZA201607765B (en) Novel macrocyclic compounds
GB201512967D0 (en) Rotary encoder
IL256205B (en) Positional encoder
EP3382222A4 (en) ROTATION RING
EP3338805A4 (en) Drug complex
GB201602090D0 (en) Powder
HK1210657A2 (en) Ring sizer
GB2550216B (en) Teething Ring
GB201615912D0 (en) Pharmaceutical compound
GB201615916D0 (en) Pharmaceutical compound
GB201715210D0 (en) Macrocyclic compounds
AU201812909S (en) Ring
GB201704121D0 (en) Macrocyclic compounds
GB201704125D0 (en) Macrocyclic Compounds
GB201720326D0 (en) Nimb Ring
AU201715227S (en) Ring
AU201715228S (en) Ring
AU201613163S (en) Ring
TWM533982U (en) Rotary bed structure
GB201602871D0 (en) Pharmaceutical compounds
GB201602861D0 (en) Pharmaceutical compounds